

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

KGN

RRID:CVCL_0375

Type: Cell Line

Proper Citation

RRID:CVCL_0375

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0375

Proper Citation: RRID:CVCL_0375

Description: Cell line KGN is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian granulosa cell tumor

Defining Citation: [PMID:11145608](#), [PMID:15541573](#), [PMID:18980698](#), [PMID:19956657](#), [PMID:20098707](#), [PMID:20164919](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KGN

Cross References: BTO:BTO_0005671, CLO:CLO_0051454, EFO:EFO_0022440, MCCL:MCC:0000270, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472163, cancercellines:CVCL_0375, Cell_Model_Passport:SIDM00302, ChEMBL-Cells:ChEMBL3308155, ChEMBL-Targets:ChEMBL2366154, CLS:305446, Cosmic:924186, Cosmic:1149409, Cosmic:1213591, Cosmic:1305320, Cosmic:1312287, Cosmic:1429993, Cosmic:2368538, Cosmic:2697832, Cosmic-CLP:924186, DepMap:ACH-002149, EGA:EGAS00001000978, FANTOM5_SSTAR:10624-108H3, GDSC:924186, GEO:GSM1669985, IARC_TP53:27560, KYinno:KC-3936, LINCS_LDP:LCL-1297, PharmacDB:KGN_746_2019, PRIDE:PXD030304, PubChem_Cell_line:CVCL_0375,

RCB:RCB1154, Ubigene:YC-C051, Wikidata:Q54899838

ID: CVCL_0375

Record Creation Time: 20220427T220702+0000

Record Last Update: 20260905T180936+0000

Ratings and Alerts

No rating or validation information has been found for KGN.

No alerts have been found for KGN.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

TanTai W, et al. (2026) SIRT5-RAC2 Axis Drives Monocyte-to-Macrophage Differentiation to Promote Inflammatory Injury in Premature Ovarian Insufficiency. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e18417.

Wen X, et al. (2026) A Nanoparticle-Integrated Complete Manufacturing Pipeline of Chemically Engineered Exosomes. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(32), e16075.

Zhang Q, et al. (2026) IFN- γ -induced AIM2-PANoptosis in granulosa cells leads to ovulatory dysfunction in polycystic ovary syndrome. Biochemical pharmacology, 250(Pt 2), 118039.

Hu Q, et al. (2026) Inhibition of IGFBP4 in Granulosa Cells Improves Reproductive Performance and Maintains Fertility With Age via YAP Signaling. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e10226.

Jiang M, et al. (2026) Hydrogen-generating nanomodulators for metabolic repair and functional recovery in ovarian tissue transplantation. Journal of nanobiotechnology, 24(1).

Ying YY, et al. (2026) Circadian rhythm disruption impairs ovarian follicular development via NAD⁺ metabolic reprogramming. EBioMedicine, 126, 106200.

Liu Q, et al. (2026) Mesenchymal stem cells reverse ovarian dysfunction by inhibiting autophagy in polycystic ovary syndrome mice. Stem cell research & therapy.

Sacha CR, et al. (2025) Anti-Müllerian hormone binds heat shock protein glucose-regulated protein 78 in human follicular fluid. *Journal of assisted reproduction and genetics*, 42(7), 2449.

Tsai YR, et al. (2025) Differential Effects of Canonical Androgens and 11-Ketotestosterone on Reproductive Phenotypes and Folliculogenesis in Mouse Model of PCOS. *Biomedicines*, 13(5).

Tsai YR, et al. (2025) Hyperandrogenism in polycystic ovary syndrome augments Estrogen synthesis through AR-FOXL2-mediated activation of the aromatase gene in granulosa cells. *Journal of ovarian research*, 18(1), 200.

Cluzet V, et al. (2025) Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways. *Molecular cancer therapeutics*, 24(8), 1197.

Amarilla-Quintana S, et al. (2025) CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds. *Molecular oncology*, 19(4), 1092.

Rahman NA, et al. (2025) Targeted destruction of follicle stimulating hormone receptor-positive cancer cells in vitro and in vivo by a lytic peptide Phor21-FSH α conjugate. *Molecular medicine (Cambridge, Mass.)*, 31(1), 224.

Chen Q, et al. (2025) Aberrant downregulation of Y-box binding protein 1 expression impairs the cell cycle in an m5C-dependent manner in human granulosa cells from patients with primary ovarian insufficiency. *Cellular and molecular life sciences : CMLS*, 82(1), 206.

Herman L, et al. (2024) A cellular model provides insights into the pathogenicity of the oncogenic FOXL2 somatic variant p.Cys134Trp. *British journal of cancer*.

Yang L, et al. (2024) GRIM19 deficiency aggravates metabolic disorder and ovarian dysfunction in PCOS. *Biochimica et biophysica acta. Molecular basis of disease*, 1870(4), 167063.

Xiang Y, et al. (2024) Interleukin-1 increases SERPINE1 expression in human granulosa-lutein cell via P50/P52 signaling pathways. *Molecular and cellular endocrinology*, 591, 112274.

Weidner AE, et al. (2024) Paxillin regulates androgen receptor expression associated with granulosa cell focal adhesions. *Molecular human reproduction*, 30(5).

Chen Q, et al. (2024) Downregulation of homeobox A1 in human granulosa cells is involved in diminished ovarian reserve through promoting cell apoptosis and mitochondrial dysfunction. *Molecular and cellular endocrinology*, 580, 112084.

Wan S, et al. (2023) Interleukin-1 increases cyclooxygenase-2 expression and prostaglandin E2 production in human granulosa-lutein cell via nuclear factor kappa B/P65 and extracellular signal-regulated kinase 1/2 signaling pathways. *Molecular and cellular endocrinology*, 566-567, 111891.